GlassScriptPhysician profile
Janna D Miller
NPI 1801935440
$2,845.78
in general payments reported to CMS, 2019-2025
25 companies · $613 in 2025
The $613 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $166 · 2022: $571 · 2023: $752 · 2024: $745 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,109.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,148.36 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $339.70 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $191.83 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $133.69 | 2022-2024 | Rexulti |
| Lilly USA, LLC | $128.76 | 2021-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $125.23 | 2022-2024 | |
| Mylan Specialty L.P. | $108.89 | 2022-2023 | Yupelri |
| Lundbeck LLC | $86.18 | 2023-2025 | Rexulti |
| Medtronic, INC. | $74.23 | 2021-2025 | Minimed 780g |
| Exact Sciences Corporation | $68.10 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $62.06 | 2022-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.04 | 2022-2024 | Xifaxan |
| Axsome Therapeutics, INC. | $48.12 | 2025 | Auvelity |
| Viatris Specialty LLC | $35.31 | 2025 | Yupelri |
| Glaxosmithkline, LLC. | $28.30 | 2024 | Arexvy, Trelegy Ellipta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $27.18 | 2024 | Austedo Xr |
| Verona Pharma, INC. | $26.97 | 2025 | Ohtuvayre |
| Xeris Pharmaceuticals, INC. | $24.02 | 2022 | |
| Neurocrine Biosciences, INC. | $23.99 | 2022 | |
| Abbott Laboratories | $23.44 | 2022 | |
| Pfizer INC. | $23.12 | 2025 | |
| Seqirus USA INC | $18.55 | 2024 | Flucelvax |
| Sunovion Pharmaceuticals INC. | $15.82 | 2022 | |
| Dexcom, INC. | $15.80 | 2025 | Dexcom G6 Transmitter |
| Neurelis, INC. | $15.09 | 2023 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janna Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.